Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121659) titled 'A Clinical Study of Tislelizumab With or Without Anti-Angiogenic Agents as Adjuvant Therapy After Neoadjuvant Treatment and Surgery in Patients With stage II-III Non-Small Cell Lung Cancer' on April 1.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: General Hospital of Ningxia Medical University
Condition:
Lung Cancer
Intervention:
Group A: pCR after neoadjuvant therapy:None
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2026-04-01
Target Sample Size: Group A: pCR after neoadjuvant therapy:30;Group B: No pCR was achieved after neoadjuvant therapy:30;...